BG
BIIB icon

Bellevue Group’s Biogen BIIB Stock Holding History

Bellevue Group’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-160
Closed -$7K – 210
2020
Q1 		$7K Hold
160
– – ﹤0.01% 215
2019
Q4 		$8K Buy
+160
New +$44.4K ﹤0.01% 216

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bellevue Group's BIIB Position: Q1 2026 in Review

Bellevue Group increased its Biogen (BIIB) stake by 2.5% in Q1 2026, buying an estimated $16.2K and bringing the position to 3,653 shares worth $670K. The position accounts for 0.02% of the portfolio, ranked #102.

Bellevue Group first reported a position in BIIB in Q1 2016 and has held it in 40 quarters since. The position peaked at $183M in Q2 2021. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Bellevue Group held 3,653 shares of Biogen worth $670K as of Q1 2026.
  • Bellevue Group bought 88 Biogen shares in Q1 2026, an estimated $16.2K.
  • Biogen made up 0.02% of Bellevue Group's portfolio in Q1 2026, its #102 holding.
  • Bellevue Group first reported a position in Biogen in Q1 2016 and has held it in 40 quarters since.
  • Bellevue Group's Biogen position peaked at $183M in Q2 2021.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.